Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • ROOMS:

Apollomics Starts China Trial of Immunotherapy for AML

Apollomics, a Bay Area-Hangzhou biopharma, started a China Phase I trial of uproleselan in patients with relapsed or refractory acute myeloid leukemia (AML). In 2020, Apollomics acquired China rights to uproleselan from GlycoMimetics in a two-drug, $189 million deal. Both drugs are novel E-selectin-based immunotherapies aimed at leukemia. Uproleselan is designed to block E-selectin from binding with blood cancer cells, which causes drug resistance. It will be administered along with chemotherapy. Apollomics was incubated by OrbiMed Asia to develop cancer immunotherapies. More details.... Stock Symbol: (NSDQ: GLYC) Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Copyright © 2010-2020 & California Media Partners, LLC. All rights reserved.